Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
RADIANCE Continued Access Protocol
NCT05017935 · View on ClinicalTrials.gov ↗
Study Summary
RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects with uncontrolled hypertension despite the prescription of antihypertensive medications.
Conditions Studied
Interventions
- DEVICE Renal Denervation
Study Locations (20)
California
- Cardiovascular Institute of San Diego — Chula Vista
- Cedars-Sinai Medical Center — Los Angeles
- Sutter Health — Sacramento
- Pacific Heart Institute — Santa Monica
Florida
- The Cardiac and Vascular Institute — Gainesville
- Baptist Hospital of Miami — Miami
- Orlando Health — Orlando
Illinois
- Northwestern University — Chicago
- Prairie Education and Research Cooperative — Springfield
- SIU Medicine — Springfield
Massachusetts
- Boston Medical Center — Boston
- The Brigham and Women's Hospital — Boston
- UMASS Memorial Medical Center — Worcester
Maryland
- Lifebridge Health — Baltimore
- Tidal Health — Salisbury
Connecticut
- Bridgeport Hospital — Bridgeport
Georgia
- Emory — Atlanta
Indiana
- Parkview Research Center — Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-05-04 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05017935
The ClinicalTrials.gov registry entry for NCT05017935 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ReCor Medical, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention — of which Renal Denervation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05017935 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05017935 about?
NCT05017935 is a clinical study titled "RADIANCE Continued Access Protocol". RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects with uncontrolled hypertension despite the prescription of antihyperten...
What is the current status of trial NCT05017935?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2022-05-04. Estimated completion is 2028-12-31.
What conditions does trial NCT05017935 study?
This clinical trial studies the following conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases, Hypertension, Resistant to Conventional Therapy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05017935?
The interventions under investigation include: Renal Denervation (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05017935?
This trial is sponsored by ReCor Medical, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05017935 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.